Follicular lymphoma: time for a re-think?

Jaffe, 2001, Pathology and genetics of tumours of haematopoietic and lymphoid tissues Anderson, 1998, Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project, Ann Oncol, 9, 717, 10.1023/A:1008265532487 Cartwright, 1999, The rise in incidence of lymphomas in Europe 1985–1992, Eur J Cancer, 35, 627, 10.1016/S0959-8049(98)00401-8 Zahm, 1992, Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia, Am J Public Health, 82, 990, 10.2105/AJPH.82.7.990 Zahm, 1990, A case-control study of non-Hodgkin’s lymphoma and the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) in eastern Nebraska, Epidemiology, 1, 349, 10.1097/00001648-199009000-00004 Morton, 2003, Cigarette smoking and risk of non-Hodgkin lymphoma subtypes among women, Br J Cancer, 89, 2087, 10.1038/sj.bjc.6601388 Schroeder, 2001, Agricultural risk factors for t(14;18) subtypes of non-Hodgkin’s lymphoma, Epidemiology, 12, 701, 10.1097/00001648-200111000-00020 Halaas, 2003, Follicular lymphoma grade 3 is not equivalent to follicular large cell lymphoma: comparison of the WHO and IWF classification system, Blood, 102 Mann, 1983, Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method, Hematol Oncol, 1, 187, 10.1002/hon.2900010209 Chau, 2003, Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?, Br J Cancer, 89, 36, 10.1038/sj.bjc.6601006 Bartlett, 1994, Follicular large-cell lymphoma: intermediate or low grade?, J Clin Oncol, 12, 1349, 10.1200/JCO.1994.12.7.1349 Martin, 1995, Prognostic value of cellular proliferation and histologic grade in follicular lymphoma, Blood, 85, 3671, 10.1182/blood.V85.12.3671.bloodjournal85123671 Miller, 1997, Follicular lymphomas: do histologic subtypes predict outcome, Hematol Oncol Clin North Am, 11, 893, 10.1016/S0889-8588(05)70468-8 Hans, 2003, A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival, Blood, 101, 2363, 10.1182/blood-2002-07-2298 Armitage, 1998, New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project, J Clin Oncol, 16, 2780, 10.1200/JCO.1998.16.8.2780 Horning, 1984, The natural history of initially untreated low-grade non-Hodgkin’s lymphomas, N Engl J Med, 311, 1471, 10.1056/NEJM198412063112303 Johnson, 1995, Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center, J Clin Oncol, 13, 140, 10.1200/JCO.1995.13.1.140 Yuen, 1995, Long-term survival after histologic transformation of low-grade follicular lymphoma, J Clin Oncol, 13, 1726, 10.1200/JCO.1995.13.7.1726 A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909–18 Velasquez, 2003, Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501, J Clin Oncol, 21, 1996, 10.1200/JCO.2003.09.047 Cleary, 1986, Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas, J Exp Med, 164, 315, 10.1084/jem.164.1.315 Heckman, 2003, Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2, Cancer Res, 63, 6666 McDonnell, 1991, Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18), Nature, 349, 254, 10.1038/349254a0 Egle, 2004, VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia, Blood, 103, 2276, 10.1182/blood-2003-07-2469 Schuler, 2003, Chromosomal translocation t (14;18) in healthy individuals, Semin Cancer Biol, 13, 203, 10.1016/S1044-579X(03)00016-6 Husson, 2002, Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays, Blood, 99, 282, 10.1182/blood.V99.1.282 Martinez-Climent, 2003, Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations, Blood, 101, 3109, 10.1182/blood-2002-07-2119 Lossos, 2002, Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes, Proc Natl Acad Sci USA, 99, 8886, 10.1073/pnas.132253599 Elenitoba-Johnson, 2003, Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy, Proc Natl Acad Sci USA, 100, 7259, 10.1073/pnas.1137463100 Lopez-Guillermo, 2000, Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series, Ann Oncol, 11, 137, 10.1023/A:1008369623425 Price, 1991, The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma, J Clin Oncol, 9, 1527, 10.1200/JCO.1991.9.9.1527 Johnson, 1999, Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study, Ann Oncol, 10, 1349, 10.1023/A:1008385924543 Ladetto, 2003, Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone, Exp Hematol, 31, 784, 10.1016/S0301-472X(03)00191-7 Vaughan Hudson, 1994, Clinical stage 1 non-Hodgkin’s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy, Br J Cancer, 69, 1088, 10.1038/bjc.1994.213 Wilder, 2001, Long-term results with radiotherapy for stage I–II follicular lymphomas, Int J Radiat Oncol Biol Phys, 51, 1219, 10.1016/S0360-3016(01)01747-3 Mac Manus, 1996, Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University, J Clin Oncol, 14, 1282, 10.1200/JCO.1996.14.4.1282 Seymour, 2003, Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin’s lymphoma, J Clin Oncol, 21, 2115, 10.1200/JCO.2003.07.111 Gandhi, 1999, The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients, Bone Marrow Transplant, 23, 9, 10.1038/sj.bmt.1701530 Brice, 1997, Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte, J Clin Oncol, 15, 1110, 10.1200/JCO.1997.15.3.1110 Young, 1988, The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment, Semin Hematol, 25, 11 Ardeshna, 2003, Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial, Lancet, 362, 516, 10.1016/S0140-6736(03)14110-4 Hoppe, 1981, The treatment of advanced stage favorable histology non-Hodgkin’s lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation, Blood, 58, 592, 10.1182/blood.V58.3.592.592 Morrison, 1993, Combination chemotherapy in the treatment of follicular low-grade lymphoma, Leuk Lymphoma, 10, 29, 10.3109/10428199309149108 Klasa, 2002, Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin’s lymphoma previously treated with an alkylating agent or alkylator-containing regimen, J Clin Oncol, 20, 4649, 10.1200/JCO.2002.11.068 Pan, 2003, CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin’s lymphomas, Leuk Lymphoma, 44, 967, 10.1080/1042819031000067710 Baldini, 1997, A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin’s lymphoma. Gruppo Italiano per lo Studio dei Linfomi, Cancer, 79, 1234, 10.1002/(SICI)1097-0142(19970315)79:6<1234::AID-CNCR24>3.0.CO;2-# Horning, 2000, Follicular lymphoma: have we made any progress, Ann Oncol, 11, 23, 10.1023/A:1008385202953 Tondini, 2000, Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin’s lymphoma: a phase II randomized study, Ann Oncol, 11, 231, 10.1023/A:1008325110921 Hochster, 2000, Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up – a report from the Eastern Cooperative Oncology Group, J Clin Oncol, 18, 987, 10.1200/JCO.2000.18.5.987 Tsimberidou, 2002, Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma, Blood, 100, 4351, 10.1182/blood-2001-12-0269 Bremer, 2002, High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin’s-lymphomas, J Cancer Res Clin Oncol, 128, 603, 10.1007/s00432-002-0378-6 Rummel, 2003, Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas, Blood, 102 Aviles, 1996, Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival, Leuk Lymphoma, 20, 495, 10.3109/10428199609052435 Arranz, 1998, Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin’s lymphoma: results from a prospective, multicenter trial with double randomization, J Clin Oncol, 16, 1538, 10.1200/JCO.1998.16.4.1538 Solal-Celigny, 1998, Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 Trial, J Clin Oncol, 16, 2332, 10.1200/JCO.1998.16.7.2332 Fisher, 2000, Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin’s lymphoma: results of the Southwest Oncology Group randomized phase III study 8809, J Clin Oncol, 18, 2010, 10.1200/JCO.2000.18.10.2010 Allen, 2001, Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin’s lymphoma, J Immunother, 24, 58, 10.1097/00002371-200101000-00007 Peterson, 1997, Cyclophosphamide versus cyclophosphamide plus interferon alfa2b in follicular lymphoma: an intergroup phase III trial (CALGB 8691 and EST 7486), Proc Am Soc Clin Oncol, 16 Bubien, 1993, Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes, J Cell Biol, 121, 1121, 10.1083/jcb.121.5.1121 Kipps, 2002, Advances in classification and therapy of indolent B-cell malignancies, Semin Oncol, 29, 98, 10.1053/sonc.2002.30146 Reff, 1994, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood, 83, 435, 10.1182/blood.V83.2.435.435 Maloney, 2003, Rituximab for follicular lymphoma, Curr Hematol Rep, 2, 13 Selenko, 2001, CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells, Leukemia, 15, 1619, 10.1038/sj.leu.2402226 Shan, 1998, Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies, Blood, 91, 1644, 10.1182/blood.V91.5.1644 Miller, 2003, Design, construction, and in vitro analyses of multivalent antibodies, J Immunol, 170, 4854, 10.4049/jimmunol.170.9.4854 Gopal, 2004, Fenretinide enhances rituximab-induced cytotoxicity against B cell lymphoma xenografts via a caspase-dependent mechanism, Blood, 103, 3516, 10.1182/blood-2003-08-2795 Liu, 2003, Antibody dependent cellular cytotoxicity and natural killer cell activity in patients with recurrent indolent lymphoma receiving rituximab in combination with GM-CSF, Blood, 102 Multani, 1998, Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies, Clin Cancer Res, 4, 2599 Byrd, 1999, Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance, J Clin Oncol, 17, 791, 10.1200/JCO.1999.17.3.791 Leo, 2004, Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma, Eur J Haematol, 73, 251, 10.1111/j.1600-0609.2004.00293.x Lemieux, 2004, Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma, Bone Marrow Transplant, 10.1038/sj.bmt.1704467 Dervite, 2001, Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab, N Engl J Med, 344, 68, 10.1056/NEJM200101043440120 Tsutsumi, 2004, Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin’s lymphoma, Ann Hematol, 83, 58, 10.1007/s00277-003-0748-4 Davis, 2000, Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment, J Clin Oncol, 18, 3135, 10.1200/JCO.2000.18.17.3135 Hainsworth, 2003, Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies, Blood, 102 Kennedy, 2002, Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin’s lymphoma: a retrospective review, Br J Haematol, 119, 412, 10.1046/j.1365-2141.2002.03843.x Cartron, 2002, Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene, Blood, 99, 754, 10.1182/blood.V99.3.754 Ghielmini, 2003, The genotype of the IgG Fc receptor is predictive of event free survival after treatment with rituximab in patients with follicular lymphoma participating in Study SAKK 35/98, Blood, 102 Giles, 2003, Circulating CD20 and CD52 in patients with non-Hodgkin’s lymphoma or Hodgkin’s disease, Br J Haematol, 123, 850, 10.1046/j.1365-2141.2003.04683.x Gordan, 2002, A phase II trial of individualized pharmacokinetic dosing of rituximab maintenance for patients with CD-20 positive lymphoproliferative disorders, Blood, 100 Colombat, 2001, Solal-Celigny (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation, Blood, 97, 101, 10.1182/blood.V97.1.101 Marcus, 2003, An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP Chemotherapy alone in untreated stage III/IV follicular Non-Hodgkins lymphoma, Blood, 102 Hiddemann, 2003, Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG, Blood, 102 Rambaldi, 2003, Long term improvement of clinical outcome of follicular lymphoma patients achieving a molecular response after sequential CHOP and rituximab treatment: predictive value of real time quantitative PCR To identify responding patients, Blood, 102 Czuczman, 2003, Patients with low-grade NHL treated with rituximab+CHOP experience prolonged clinical and molecular remission, Blood, 102 Liu, 2003, Stage IV indolent lymphoma: 25 years of treatment progress, Blood, 102 McLaughlin, 1998, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol, 16, 2825, 10.1200/JCO.1998.16.8.2825 Feuring-Buske, 2000, IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group, Ann Hematol, 79, 493, 10.1007/s002770000163 Piro, 1999, Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma, Ann Oncol, 10, 655, 10.1023/A:1008389119525 Bremer, 2003, Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin’s lymphoma: a phase II study, Anticancer Drugs, 14, 809, 10.1097/00001813-200311000-00006 Forstpointner R, Dreyling MH, Repp R, Hermann S, Haenel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas – results of a prospects randomized study of the German low grade lymphoma study group (GLSG). Blood 2004;July 29:[Epub ahead of print] Hainsworth, 2002, Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma, J Clin Oncol, 20, 4261, 10.1200/JCO.2002.08.674 Ghielmini, 2004, Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly×4 schedule, Blood, 10.1182/blood-2003-10-3411 Cheson, 2003, Radioimmunotherapy of non-Hodgkin lymphomas, Blood, 101, 391, 10.1182/blood-2002-06-1793 Campbell, 2003, Monoclonal antibody therapy for lymphoma, Blood Rev, 17, 143, 10.1016/S0268-960X(03)00005-5 Hohenstein, 2003, Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab, Semin Oncol, 30, 39, 10.1053/sonc.2003.23801 Wiseman, 2003, Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials, J Nucl Med, 44, 465 Witzig, 2003, Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin’s lymphoma, J Clin Oncol, 21, 1263, 10.1200/JCO.2003.08.043 Forero, 2004, Phase I trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin’s lymphoma, Blood, 10.1182/blood-2003-09-3284 Kaminski, 2001, Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas, J Clin Oncol, 19, 3918, 10.1200/JCO.2001.19.19.3918 Press, 2003, Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas, Blood, 102, 1606, 10.1182/blood-2003-01-0287 Witzig, 2002, Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas, J Clin Oncol, 20, 2453, 10.1200/JCO.2002.11.076 Witzig, 2002, Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma, J Clin Oncol, 20, 3262, 10.1200/JCO.2002.11.017 Ansell, 2002, Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin’s lymphoma, J Clin Oncol, 20, 3885, 10.1200/JCO.2002.10.143 Press, 2000, A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas, Blood, 96, 2934, 10.1182/blood.V96.9.2934 Press, 1993, Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support, N Engl J Med, 329, 1219, 10.1056/NEJM199310213291702 Gopal, 2003, High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis, Blood, 102, 2351, 10.1182/blood-2003-02-0622 Sebban C, Belanger C, Brousse N, Mounier N, Brice P, Haioun C, et al. Comparison of CHVP+interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF94 Trial (G.E.L.A. Study Group). Blood 2003; 102 [abstract 354] Ganz, 2003, Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas, J Clin Oncol, 21, 3512, 10.1200/JCO.2003.01.044 Deconinck E, Foussard C, Bertrand P, Cornillet-Lefebvre, Milpied N, Escoffre-Barbe M, et al. Value of autologous stem cell transplantation in first line therapy of follicular lymphoma with high tumor burden: final results of the randomized GOELAMS 064 Trial. Blood 2003;102 [abstract 865] Schouten, 2003, High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial, J Clin Oncol, 21, 3918, 10.1200/JCO.2003.10.023 Brenner, 1993, Gene-marking to trace origin of relapse after autologous bone-marrow transplantation, Lancet, 341, 85, 10.1016/0140-6736(93)92560-G Freedman, 1996, High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission, Blood, 88, 2780, 10.1182/blood.V88.7.2780.bloodjournal8872780 Belhadj, 2004, Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin’s lymphoma: a single institution study, Ann Oncol, 15, 504, 10.1093/annonc/mdh090 Scott, 1998, A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study, Bone Marrow Transplant, 22, 273, 10.1038/sj.bmt.1701327 Gandhi, 2003, Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation, Blood, 102, 3427, 10.1182/blood-2002-12-3689 van Besien, 2003, Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma, Blood, 102, 3521, 10.1182/blood-2003-04-1205 Khouri, 2001, Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality, Blood, 98, 3595, 10.1182/blood.V98.13.3595 Robinson, 2002, Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation, Blood, 100, 4310, 10.1182/blood-2001-11-0107 Marks, 2002, The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation, Blood, 100, 3108, 10.1182/blood-2002-02-0506 Sakato, 1982, A small hypervariable segment in the variable domain of an immunoglobulin light chain stimulates formation of anti-idiotypic suppressor T cells, Proc Natl Acad Sci USA, 79, 5396, 10.1073/pnas.79.17.5396 George, 1988, Idiotypic vaccination as a treatment for a B cell lymphoma, J Immunol, 141, 2168, 10.4049/jimmunol.141.6.2168 Hsu, 1996, Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells, Nat Med, 2, 52, 10.1038/nm0196-52 Kwak, 1992, Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors, N Engl J Med, 327, 1209, 10.1056/NEJM199210223271705 Bendandi, 1999, Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma, Nat Med, 5, 1171, 10.1038/13928